
õ½Ä°ú ¾Ë·¹¸£±âÁúȯ
- ÀúÀÚ(±Û)´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ
- ÃâÆÇ»ç¿©¹®°¢
- ¹ßÇàÀÏ2012³â 03¿ù 30ÀÏ
¸¸¼ºÆó¼â¼ºÆóÁúȯ Áø·á ¹× ¿¬±¸ÀÇ ¼±µÎ ÁÖÀÚ
À¯±¤ÇÏ º´¿øÀåÀº °Ç±¹´ëº´¿ø¿¡¼ È£Èí±â-¾Ë·¹¸£±â³»°ú ±³¼ö·Î ÀçÁ÷ÇÏ¸é¼ Áø·áºÎ¿øÀå°ú º´¿øÀåÀ» ¿ªÀÓÇß´Ù. ÇöÀç ´ëÇѰáÇÙ ¹× È£Èí±âÇÐȸ ÀÌ»çÀåÀ¸·Î, Ãѹ«ÀÌ»ç¿Í COPD ¿¬±¸È¸ ȸÀå µîÀ» ¿ªÀÓÇß´Ù. COPD ¸íÀǷμ ȯÀÚ¸¦ À§ÇØ °ü·Ã ºÐ¾ßÀÇ Áø·á¿Í ¿¬±¸¸¦ Ȱ¹ßÈ÷ Çϰí ÀÖ´Ù. Áö³ 2023³â¿¡´Â ICS(ÈíÀÔ½ºÅ×·ÎÀ̵å)+LABA º´¿ë¿ä¹ý ´ëºñ LAMA »ç¿ë ÀÌÁ¡À» È®ÀÎÇÑ ÀÓ»ó ¿¬±¸·Î ±¹Á¦Àû ÁÖ¸ñÀ» ¹Þ¾Ò´Ù. ¶Ç À¯±¤ÇÏ º´¿øÀåÀÌ ÁøÇàÇÑ COPD ÄÚȣƮ ¿¬±¸´Â COPD ȯÀÚÀÇ È£ÈíÀçȰ°ú À̵¿½Ä »ê¼Ò Ä¡·á¸¦ °Ç°º¸ÇèÀû¿ëÇ׸ñÀ¸·Î ¸¸µé¸ç ȯÀÚ ±³À°À» À§ÇÑ Á¦µµÀû ¿©°ÇÀ» ¸¶·ÃÇß´Ù´Â Æò°¡¸¦ ¹Þ¾Ò´Ù.
Á¦ ¸ñ | 4õ¸¸ÀÇ ¾Ë·¹¸£±â | ||
---|---|---|---|
ÃâÆÇ»ç | °øÀúÀÚ | ¹ßÇàÀÏ | 1993³â ¹ß°£, 2005³â °³Á¤ |
Á¦ ¸ñ | Blood eosinophil count and treatment patterns of chronic obstructive pulmonary disease patients in South Korea using real-world data | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2025 | ¹ßÇ¥Áö | ±³½ÅÀúÀÚ |
Á¦ ¸ñ | Kernel conversion improves correlation between emphysema extent and clinical parameters in COPD: a multicenter cohort study | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2025 | ¹ßÇ¥Áö | ±³½ÅÀúÀÚ |
Á¦ ¸ñ | Clinical characteristics of chronic obstructive pulmonary disease patients with superoptimal peak inspiratory fow rate | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2024 | ¹ßÇ¥Áö | ±³½ÅÀúÀÚ |
Á¦ ¸ñ | Efficacy and safety of mixture of ivy leaf extract and coptidis rhizome in the treatment of acute bronchitis: multicenter, randomized, double blinded, active-controlled, parallel, therapeutic confirmatory clinical trial | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2024 | ¹ßÇ¥Áö | ±³½ÅÀúÀÚ |
Á¦ ¸ñ | Clinical Characteristics and Frequency of Chronic Obstructive Pulmonary Disease Exacerbations in Korean Patients: Findings From the KOCOSS Cohort 2012–2021 | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2024 | ¹ßÇ¥Áö | ±³½ÅÀúÀÚ |
Á¦ ¸ñ | Suboptimal peak inspiratory flow rate in dry-powder inhaler users for chronic obstructive pulmonary disease in Korea | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2024 | ¹ßÇ¥Áö | ±³½ÅÀúÀÚ |
Á¦ ¸ñ | Short-acting ¥â2-agonist prescriptions in patients with asthma: findings from the South Korean cohort of SABINA III | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2023 | ¹ßÇ¥Áö | ÁÖÀúÀÚ |
[°ü½ÉºÐ¾ß] ±¹³» ¸¸¼ºÆó¼â¼ºÆóÁúȯ ÀÎÁöµµ Çâ»ó ¹× ¿Ã¹Ù¸¥ Ä¡·á¿¡ ÀÇÇÑ °Ç° ºÎ´ã °¨¼Ò [¾÷Àû] Àü±¹ 52°³ º´¿øÀÌ Âü¿©ÇÑ ¸¸¼ºÆó¼â¼ºÆóÁúȯ ÄÚȣƮ ¿¬±¸Ã¥ÀÓÀÚ·Î ±¹³» ¸¸¼ºÆó¼â¼ºÆóÁúȯ ¿¬±¸ÀÇ ¼±µÎÁÖÀÚÀÓ
ȯÀÚÀÇ Áúº´ Ä¡·á¿Í ¸¶À½ÀÇ À§¾ÈÀ» ÇÔ²² Á¦°øÇÔ. ȯÀÚ°¡ Áø·á½Ç¿¡ Ç×»ó ¿õ½º¸é¼ µé¾î¿À°í ¿ôÀ¸¸é¼ ³ª°¥ ¼ö ÀÖµµ·Ï ³ë·ÂÇÔ
Áúº´Àº ȯÀÚÀÇ À߸øÀÌ ¾Æ´Õ´Ï´Ù. ³«½ÉÇÏÁö ¾Ê°í ¿½ÉÈ÷ Ä¡·á¿Í ÀçȰÀ» Çϸé ȸº¹ÇÒ ¼ö ÀÖ½À´Ï´Ù.
°Ç±¹´ëÇб³º´¿øÀº »óÇã À¯¼®Ã¢ ¼±»ý²²¼ ÀÏÁ¦ °Á¡±âÀÎ 1931³â ¹ÎÁ·ÁöµµÀÚµé°ú ¶æÀ» ¸ð¾Æ ±¸·áÁ¦¹Î(ÏÖûðÚÅ)°ú Àμúº¸±¹(ìÒâúÜÃÏÐ)ÀÇ Å« ¶æÀ» ´ã¾Æ ¼³¸³ÇÑ ¡®»çȸ¿µ Á߾ӽǺñÁø·á¿ø¡¯¿¡ »Ñ¸®¸¦ µÎ°í ÀÖ´Ù. 2002³â °Ç±¹´ëÇб³ ¼¿ïÄ·ÆÛ½º ³²´Ü¿¡ º´¿ø °Ç¹°À» »õ·Î Áþ±â ½ÃÀÛÇØ 2005³â 8¿ù »õ·Ó°Ô žÀ¸¸ç ÁöÇÏ4Ãþ, Áö»ó 13Ãþ ¿¬¸éÀû 2¸¸ 6300¿©ÆòÀÇ »õ °Ç±¹´ëº´¿øÀº 33°³ÀÇ Áø·á°ú¿Í 784°³ÀÇ º´»ó, 9°³ÀÇ ÁßÁ¡¼¾ÅÍ¿Í 14°³ÀÇ Áø·á¼¾ÅÍ, ÇコÄɾÅ͸¦ °®Ãß°í 430¿©¸íÀÇ ÀÇ·áÁøÀÌ Áø·á¸¦ Çϰí ÀÖ´Ù. 2009³â °©»ó¼±¾Ï¼¾ÅÍ, ´ëÀå¾Ï¼¾ÅÍ, À¯¹æ¾Ï¼¾ÅÍ µî ¾Ï¼¾Å͸¦ °³¼³Çϰí, 2017³â 11¿ù¿¡´Â ÃÖ½ÅÇü ·Îº¿ ¸ðµ¨ÀÎ 4¼¼´ë ´ÙºóÄ¡Xi¸¦ µµÀÔ, ·Îº¿¼ö¼ú ¼¾ÅÍ °¡µ¿À» ½ÃÀÛÇß´Ù. °Ç±¹´ëº´¿øÀº ´ëÀå¾Ï, À¯¹æ¾Ï, Æó¾Ï, À§¾Ï, Ç÷¾×Åõ¼®, ¸¸¼ºÆó¼â¼ºÆóÁúȯ µî ÁßÁõÁúȯ ºÐ¾ß Æò°¡¿¡¼ 1µî±ÞÀ» ±â·ÏÇϰí ÀÖÀ¸¸ç, °ñµçŸÀÓÀÌ Áß¿äÇÑ ½ÉÇ÷°üÁúȯ°ú ³úÇ÷°üÁúȯÀÇ ½Å¼ÓÁø·á½Ã½ºÅÛÀ» ¿î¿µÇÏ¸ç ±Þ¼º±â ³úÁ¹Áß ¹× °ü»óµ¿¸Æ¿ìȸ¼ú Æò°¡¿¡¼µµ 1µî±ÞÀ» À̾°í ÀÖ´Ù. Áö³ 2023³â¿¡´Â ÁßÁõÁúȯ Ä¡·á ¿ª·® °È¸¦ À§ÇØ ÁßȯÀÚ½Ç ¹× ¼ö¼ú½Ç Áõ¼³, ·Îº¿¼ö¼ú±â±â Ãß°¡ ¹× CTµî ½ÅÇüÀÇ·áÀåºñ µîÀ» µµÀÔÇß´Ù. À̾î 2024³â¿¡´Â ȯÀÚµéÀÇ ÄèÀûÇÑ È¯°æÀ» À§ÇØ º´µ¿ ȯ°æÀ» °³¼±Çϰí, 2025³â¿¡´Â ¿Ü·¡¼¾ÅÍ ÁõÃàÀ» ¾ÕµÎ°í ÀÖ´Ù.
¼¿ïƯº°½Ã ±¤Áø±¸ ´Éµ¿·Î 120-1(Ⱦ絿) °Ç±¹´ëÇб³º´¿ø